ABSTRACT The effects of oral diltiazem (360 mg/day) on exercise tolerance, left ventricular performance, and plasma lactate and catecholamine levels were studied in 13 patients with atherosclerotic coronary artery disease in a placebo-controlled, randomized, double-blind protocol. Exercise duration to the onset of ischemic ST segment depression, time to angina pectoris, and time to peak exercise improved by 120, 174, and 144 sec, respectively (p < .0001). Left ventricular ejection fraction, as determined by radionuclide angiography, increased in patients at rest from 52 + 11% (mean + SD) during placebo therapy to 58 11% during diltiazem therapy (p < .001); at peak exercise ejection fraction increased from 44 11% during placebo treatment to 52 + 15% during diltiazem therapy (p < .01). The mean plasma norepinephrine level in patients at rest increased from 498 + 221 pg/ml during placebo treatment to 667 + 272 pg/ml during diltiazem therapy (p < .05).
DILTIAZEM HYDROCHLORIDE has been shown to be effective in the treatment of exertional angina pectoris in doses of 240 mg/day.1 Although divided doses of up to 360 mg/day have been useful in treating patients with variant angina,2'3 previously reported studies have not evaluated this dose for the long-term therapy of patients with exertional angina pectoris. Dose titration studies have shown that beneficial effects of diltiazem can be demonstrated by exercise treadmill testing in patients with coronary artery disease at doses of 240 mg/day, but not at lower doses."7 Single doses of 90 to 120 mg have also been demonstrated to be effective.8 9 Little data exist concerning the effects of higher doses of diltiazem (360 mg/day) on resting hemodynamics and left ventricular performance during exercise. Therefore, the purpose of this study was to evaluate the safety, efficacy, and hemodynamic effects of 360 mg/day diltiazem in divided doses for the treatment of chronic stable exertional angina pectoris.
Materials and methods
Patient selection. Thirteen patients between the ages of 49 and 70 years (mean 61.5) were included in the study group.
Study patients were required to have had stable angina pectoris for at least 3 months, to have typical exertional chest pain relieved by nitroglycerin, and to have previous exercise treadmill test results positive for both chest pain and ischemic ST segment depression in an anterolateral precordial lead. Patients who had had a myocardial infarction in the preceding 6 months or had concurrent congestive heart failure, valvular heart disease, significant arrhythmias, or hypertension were excluded. Of the 13 patients who participated, 11 had previously documented myocardial infarctions. Of the 10 patients undergoing coronary arteriography, six had significant (> 70% diameter narrowing) three-vessel disease, one had two-vessel disease, and three had one-vessel disease. Patients provided informed consent on a form approved by the Institutional Review Board of the University of Texas Health Science Center, San Antonio.
Short-term studies. The first 2 weeks were a single-blind placebo period during which the patients took three placebo tablets four times daily. Digoxin, ,8-blocker, and long-acting nitrate therapy was stopped. The third and fourth weeks were the randomized, double-blind crossover portion of the study. Patients took either three placebo or three 30 mg diltiazem tablets four times daily. Symptom-limited exercise treadmill tests were performed by the patients at the end of each week; on another day in week 3 and week 4 rest and exercise radionuclide angiograms were recorded.
Long-term studies. After completion of the short-term studies 12 patients consented to participate in the long-term study and were treated with 90 mg diltiazem four times a day for 16 weeks (weeks 5 through 20). Treadmill tests were performed at the end of weeks 12 and 20. During week 21 patients received placebo tablets in a fashion identical to that in the short-term study and performed exercise tests. Plasma samples for measuring diltiazem levels by high-performance liquid chromatography were obtained at the end of week 20. 10 All patients had measurable diltiazem plasma levels, with a mean value of 171 + 93 ng/ml. Two patients did not complete the long-term study, one because of sudden death and one because of the side effects of diltiazem. Thus, 10 Resting and exercise catecholamine and lactate levels. In patients at rest the mean plasma norepinephrine level during placebo treatment was 498 ± 221 pg/ml, and during diltiazem therapy it rose to 667 + 272 pg/ml (p < .05). During exercise plasma norepinephrine levels rose significantly (to 1295 + 457 pg/ml) in patients on placebo (p < .0001) and in those on diltiazem therapy (to 2850 ± 1240 pg/ml, p < .0001). The exercise levels were significantly higher during the diltiazem treatment week than during the placebo week (p < .01). Similar changes were observed in epinephrine and lactate levels (table 1) .
Hemodynamic response to exercise (table 2) . Diltiazem produced no significant changes in resting supine or standing heart rates, or in the heart rates at each of the exercise end points. The mean systolic supine blood pressures in patients at rest showed no differences over the course of the short-term study, but diltiazem did potentiate the orthostatic decrease in systolic blood pressure by 7 mm Hg (p < .05). There were no differ- These data suggest that the rate-pressure product exercised to by patients on diltiazem is equal to or higher than that of patients receiving a placebo. Catecholamine and lactate levels. This study is the first report of resting and exercise plasma catecholamine and lactate levels in patients taking diltiazem. The significant increase in resting norepinephrine levels during therapy with diltiazem raises several possibilities concerning the principal mode of action of diltiazem in patients with coronary artery disease. The increase in resting norepinephrine levels in conjunction with the significant reduction in blood pressure may Our data suggest that improved left ventricular systolic performance in patients taking diltiazem may be partially due to decreases in systolic and diastolic blood pressures. Diltiazem produces only minimal negative inotropic effects during intravenous and intracoronary administration in dogs, even in high doses. 28 There were no changes in resting or peak exercise enddiastolic volumes; therefore, alterations of contractility and wall stress may not be the key factors in improving the imbalance between myocardial oxygen demand and supply in patients treated with diltiazem. However, at peak exercise in patients receiving diltiazem we found no significant decrease in blood pressure, rate-pressure product, or heart rate. Also, we found no significant change in end-diastolic volume or hemodynamic measures at peak exercise in patients taking diltiazem compared with those on placebo. The benefit seen with diltiazem during exercise may be related to favorable alterations in myocardial blood flow or aortic impedance or to alterations in oxygen consumption. Further investigations will be needed to delineate the mechanism(s) mediating improved exercise performance during therapy with diltiazem.
Complications and adverse effects. Because peripheral edema has been reported in patients taking nifedipine and verapamil,29 we were not surprised to find this side effect in patients taking diltiazem. However, ours is the first report of a high incidence of peripheral edema during diltiazem therapy. As reported by Kinoshita et al. ,3 the mechanism of this effect may be related to altered sodium excretion. The edema we observed, although common, was not a clinical problem requiring dose reduction.
In a placebo-controlled, randomized, double-blind crossover study we examined the effects of oral diltiazem (360 mg/day) on treadmill exercise performance, hemodynamic variables during exercise, and exercise radionuclide angiography. There was a significant improvement in exercise tolerance that was greater than that seen in patients in previous studies who were taking 240 mg/day of diltiazem. Resting and peak exercise ejection fractions were significantly higher during therapy with diltiazem, despite possible negative inotropic effects, and probably resulted from decreased left ventricular afterload. The drug was well tolerated in most patients, despite the common side effect of peripheral noncardiogenic edema. The mechanism of improvement in cardiac function during diltiazem therapy remains unknown, but is likely related to both a decrease in the parameters determining myocardial oxygen consumption and an improvement in blood flow to areas of myocardial ischemia.
